DOI QR코드

DOI QR Code

Trigeminal neuralgia management after microvascular decompression surgery: two case reports

  • Hwang, Victor (Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC) ;
  • Gomez-Marroquin, Erick (Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC) ;
  • Enciso, Reyes (Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of University of Southern California) ;
  • Padilla, Mariela (Herman Ostrow School of Dentistry of USC)
  • Received : 2020.09.13
  • Accepted : 2020.12.15
  • Published : 2020.12.31

Abstract

Trigeminal neuralgia (TN) involves chronic neuropathic pain, characterized by attacks of repeating short episodes of unilateral shock-like pain, which are abrupt in onset and termination. Anticonvulsants, such as carbamazepine, are the gold standard first-line drugs for pharmacological treatment. Microvascular decompression (MVD) surgery is often the course of action if pharmacological management with anticonvulsants is unsuccessful. MVD surgery is an effective therapy in approximately 83% of cases. However, persistent neuropathic pain after MVD surgery may require reintroduction of pharmacotherapy. This case report presents two patients with persistent pain after MVD requiring reintroduction of pharmacological therapy. Although MVD is successful for patients with failed pharmacological management, it is an invasive procedure and requires hospitalization of the patient. About one-third of patients suffer from recurrent TN after MVD. Often, alternative treatment protocols, including the reintroduction of medications, may be necessary to achieve improvement. This case report presents two cases of post-MVD recurrent pain. Further research is lacking on the success rates of subsequent medication therapy after MVD has proven less effective in managing TN.

Keywords

References

  1. Faryabi J, Joolhar M. Treatments' outcomes of patients suffered from trigeminal neuralgia in kerman, iran. J Dent 2014; 15: 140-6.
  2. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991; 10: 276-81. https://doi.org/10.1159/000110284
  3. Childs AM, Meaney JF, Ferrie CD, Holland PC. Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports. Arch Dis Child 2000; 82: 311-5. https://doi.org/10.1136/adc.82.4.311
  4. Mcquay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-52. https://doi.org/10.1136/bmj.311.7012.1047
  5. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebocontrolled clinical trials. Clin Ther 2003; 25: 81-104. https://doi.org/10.1016/S0149-2918(03)90011-7
  6. Guo J, Dong X, Zhao X. Treatment of trigeminal neuralgia by radiofrequency of the Gasserian ganglion. Rev Neurosci 2016; 27: 739-43. https://doi.org/10.1515/revneuro-2015-0065
  7. Hayes WJ, Ferdinand A, Neabore S, Kappes JA, Hayes KM, Berendse J. Patient case report: gabapentin-induced hypoglycemia. J Pharm Pract 2020; 1-4.
  8. Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol 2020; 19: 784-96. https://doi.org/10.1016/s1474-4422(20)30233-7
  9. Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71: 1183-90. https://doi.org/10.1212/01.wnl.0000326598.83183.04
  10. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-6. https://doi.org/10.2217/14622416.9.10.1543
  11. Lee JE, Min KR, Kim SH, Kim AH, Kim ST. Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital. Yonsei Med J 2020; 61: 875-9. https://doi.org/10.3349/ymj.2020.61.10.875
  12. Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002; 57: 451-62. https://doi.org/10.1046/j.0003-2409.2001.02399.x
  13. Cheshire WP Jr. Defining the role for gabapentin in the treatment of trigeminal neuralgia: a retrospective study. J Pain 2002; 3: 137-42. https://doi.org/10.1054/jpai.2002.122944
  14. Brid T, Sacristán De Lama MP, González N, Baamonde A. Topical gabapentin as add-on therapy for trigeminal neuralgia. a case report. Pain Med 2017; 18: 1824-6. https://doi.org/10.1093/pm/pnx013
  15. Agarwal N, Singh S, Kriplani A, Bhatla N, Singh N. Safety and efficacy of gabapentin in management of psychosomatic and sexual symptoms in postmenopausal women: a pilot study. J Midlife Health 2015; 6: 10-5.
  16. Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. BJGP Open 2020; bjgpopen20X101120.
  17. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28: 491-6. https://doi.org/10.1007/s40263-014-0164-4
  18. Holste K, Chan AY, Rolston JD, Englot DJ. Pain outcomes following microvascular decompression for drug-resistant trigeminal neuralgia: a systematic review and meta-analysis. Neurosurgery 2020; 86: 182-90. https://doi.org/10.1093/neuros/nyz075
  19. Chang B, Zhu W, Li S. Effects of depression and anxiety on microvascular decompression outcome for trigeminal neuralgia patients. World Neurosurg 2019; 128: e556-61. https://doi.org/10.1016/j.wneu.2019.04.194
  20. Wei Y, Pu C, Li N, Ning L, Cai Y, Shang H, et al. Long-term therapeutic effect of microvascular decompression for trigeminal neuralgia: Kaplan-meier analysis in a consecutive series of 425 patients. Turk Neurosurg 2018; 28: 88-93.